Sympathetic Augmentation in Hypertension
Markus P. Schlaich(Friedrich-Alexander-Universität Erlangen-Nürnberg), Murray Esler(Baker Heart and Diabetes Institute), Duncan J. Campbell(St Vincents Institute of Medical Research), Jacqui Hastings(St Vincents Institute of Medical Research), Zygmunt S. Krozowski(The Heart Research Institute), Gavin Lambert(The Alfred Hospital), David M. Kaye(The Alfred Hospital), Anuradha Aggarwal(Friedrich-Alexander-Universität Erlangen-Nürnberg), Élisabeth Lambert(Baker Heart and Diabetes Institute)
Cited by 512
Related Papers
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
|The Lancet|2010|2.2k
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
|The Lancet|2009|2.1k
Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity.
|Circulation|1986|1k
Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions
|Physiological Reviews|1990|792
Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
|New England Journal of Medicine|2009|774